Key Highlights
- Co-Diagnostics (CODX) shares increased 9.43% to reach $2.90 during Friday’s premarket session
- CoSara Diagnostics, the company’s Indian partnership, secured rights to distribute products across Bangladesh, Pakistan, Nepal, and Sri Lanka
- The territorial agreement increases CoSara’s potential South Asian market reach to approximately $13 billion
- The expansion focuses on introducing the PCR Pro® point-of-care system and SARAGENE® diagnostics suite, subject to local regulatory clearances
- CoSara has scheduled a virtual distributor briefing for Q2 2026, followed by an in-person training event during summer 2026
Shares of Co-Diagnostics (CODX) surged 9.43% to $2.90 during premarket hours Friday following news that its Indian collaborative venture secured distribution rights across four additional South Asian nations.
CoSara Diagnostics Pvt. Ltd., a partnership between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), finalized an arrangement to broaden its distribution footprint throughout South Asia. The agreement encompasses Bangladesh, Pakistan, Nepal, and Sri Lanka.
This territorial expansion elevates CoSara’s projected addressable market across the region to roughly $13 billion, according to company estimates combined with independent market intelligence.
The strategic move aims to facilitate market entry for two flagship offerings: the CoSara PCR Pro® point-of-care diagnostic system and the SARAGENE® testing portfolio. Commercial availability in each territory remains contingent upon obtaining appropriate regulatory authorizations.
CoSara is actively building distribution infrastructure throughout these four nations. Efforts include navigating regulatory frameworks, pinpointing priority customer demographics, and forging partnerships with regional distributors.
Executive Perspectives on Regional Growth
Mohal Sarabhai, Chief Executive of CoSara, emphasized that South Asia faces substantial and expanding demand for convenient, non-invasive molecular diagnostic solutions. He highlighted tuberculosis screening, HPV detection, and respiratory infection testing as critical focus areas.
Dwight Egan, CEO of Co-Diagnostics, characterized the agreement as integral to a broader infrastructure-centric approach. The organization is establishing local production capabilities and distribution networks ahead of commercial launches—a blueprint being executed across the United States, South Asia, and MENA regions.
Egan indicated the strategy positions Co-Dx to achieve global scalability for its PCR point-of-care technology platform.
To facilitate distributor recruitment, CoSara intends to conduct a virtual informational briefing during Q2 2026. A face-to-face distributor summit and training program will follow later that summer.
Current Stock Performance
CODX had been hovering near its 52-week bottom of $2.04 prior to Friday’s premarket activity. The 9.43% uptick elevated shares to $2.90.
It bears mentioning that the PCR Pro® and associated platform technologies remain under FDA consideration and are not currently commercially available.
Last month, Co-Diagnostics secured a Japanese patent protecting its PCR platform innovations. Previously, the firm successfully restored its NASDAQ listing compliance following questions about its continued eligibility.
The $13 billion market opportunity figure derives from internal projections supplemented by external market analysis. Actual revenue generation will hinge on regulatory decisions and the speed of distributor network development across the four newly designated countries.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
